如何引证项目

Intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion in Chinese patients

   
@article{YKXB3502,
	author = {Jia-Kang Wang 和 Tzu-Lun Huang 和 Pei-Yuan Su 和 Pei-Yao Chang 和 Ying-Yu Tseng},
	title = {Intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion in Chinese patients},
	journal = {眼科学报},
	volume = {30},
	number = {2},
	year = {2015},
	keywords = {},
	abstract = {Purpose: To investigate the short-term efficacy and safety of intravitreal aflibercept in a case series of patients from Taiwan, China, with macular edema secondary to branch retinal vein occlusion (BRVO) . Methods: A total of 32 patients with macular edema associated with BRVO, without prior macular laser or other intervention, were enrolled consecutively from September 2013 to February 2015. The cases received single 2 mg injections of intravitreal aflibercept. Primary outcome measures included changes in central foveal thickness (CFT; 1 mm increments by spectral-domain optic coherence tomography) and best corrected visual acuity (BCVA), determined at 1, 2, and 3 months after the injection. Complications after injections were recorded. The changes in CFT and BCVA were compared with Wilcoxon sign-rank tests. Results: The CFT was significantly reduced and the BCVA was significantly improved at 1, 2, and 3 months after injection (all p < 0.05). Tomography findings revealed no recurrence within 3 months. No systemic thromboembolic events, elevated intraocular pressure, retinal detachment, or infectious endophthalmitis occurred following injection. Conclusion: Single intravitreal aflibercept may be useful in treating macular edema associated with BRVO within 3 months. No adverse systemic or ocular effects were found in this case series.},
	url = {https://ykxb.amegroups.com/article/view/3502}
}